key: cord-0044326-u4ft4htl
authors: Greenhawt, Matthew; Shaker, Marcus
title: Perspective: Keeping Risk in Context While Rethinking the Setting of Asthma Biologics in Patient-Centered Care
date: 2020-06-01
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2020.05.029
sha: 8d90d051b8ffffc7194a3900d975e03f0afb8735
doc_id: 44326
cord_uid: u4ft4htl

nan

Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, Allergenis, Aravax, Glaxo Smith Kline, Prota, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, the Eurpoean Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters.

Asthma is a common disease, affecting 8% to 9% of the US population.(1) Among these 1 individuals, 5-10% have severe asthma and a more significant burden of disease, leading to 2 increased costs and impaired quality of life.(2) Despite trigger identification, allergen 3 avoidance, and inhaled corticosteroids, even highly adherent patients fail to achieve adequate 4 asthma control.(2) Asthma biologics to treat severe asthma represent an effective strategy 5 mitigate the risk of more severe asthma-related consequences. Omalizumab remained the only FDA approved biologic available for patients with severe 12 asthma until 2015, when mepolizumab was approved for patients with severe eosinophilic 13 asthma. Despite no association with anaphylaxis, the mepolizumab prescribing information 14 also recommended it be administered by a healthcare professional, with post-injection 15 monitoring. In 2019, with approval of a prefilled syringe, home-administration of mepolizumab 16 became an option, joining dupilumab, approved for home use in 2017. In the past year, 17 benralizumab was also approved for home use in the United States, and in Europe an 18 omalizumab pre-filled syringe is approved for home use from the fourth dose onward. (3) In 19 2020, the US Food and Drug Administration issued a letter to healthcare providers allowing for 20 temporary self-administration of omalizumab during the COVID-19 pandemic for select patients 21 with moderate to severe asthma. These collective actions imply safety of home biologic use.

For the allergist, this would represent a fundamental evolution in using asthma biologics, albeit 23 one that may alter in-office revenue streams. For the patient, this could offer opportunities to 24 improve access to treatments previously limited by logistics, particularly in the setting of a 25 global pandemic. 26

Balancing access to home asthma biologic therapy while managing unexpected potential 27 drug-induced anaphylaxis from these agents is difficult. (3) The standard practice has been 28 office-based omalizumab administration/observation, which prioritizes additional safety over 29 potential logistical inconvenience and access for many patients who needed an asthma biologic. 30

The bigger question is if the risk of anaphylaxis remains truly great enough to justify such policy. 31

The care paradigm that has evolved has seemed reasonable and is well accepted, but the 32 danger is that this pathway was created without explicitly considering patient values and Further research is needed to understand if home biologics access will improve 79 adherence, given concerns that adherence may worsen without direct supervision, or if more 80 adverse events will occur attributable to loss of experienced nursing staff triage prior to 81

Trends and Disparities in Asthma Biologic Use in the United States

Selecting the right biologic for your patients with severe asthma

Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab

Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population

Engaging Patient Partners In State of the Art Allergy Care: Finding Balance When Discussing Risk